Amgen Inc. (AMGN)
Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen Inc. (AMGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Amgen Inc. (AMGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Got $10,000? Put It in These Dividend Stocks Now
If you have $10,000 that you won't need to spend anytime soon, there are ways to derive passive income from that money.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Amgen (AMGN) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
Amgen ( AMGN ) is having a moment. The biotech bellwether is trading near fresh 52-week highs, up roughly 8% in the latest session, and the tape is sending a clear message: institutions are leaning in.
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
Amgen delivers Q4 earnings and revenue beat, driven by strong drug volumes, as attention turns to its late-stage MariTide obesity studies.
